Clinical Trial Update: Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 biodistribution and pharmacokinetic study evaluated the PSMA-targeted PET tracer 18F-DCFBC in patients with advanced prostate cancer (study completed)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 18F-DCFBC (PSMA-targeted radiolabeled PET tracer using Fluorine-18)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Prostate Cancer | Phase 1 | Status: COMPLETED